Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ZD03 in Healthy Volunteers
NCT04693455Phase 1Completed
- Sponsor
- Zhendong Group
- Start
- Nov 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZD03 in multiple sclerosis (MS) (7 cohorts), sponsored by Zhendong Group. Primary endpoints: Safety and Tolerability up to 14 days, Clinically Significant Vital Sign Abnormalities at Day 7 and 5 more. Started Nov 2019; status: completed.
02
Drugs
ZD03
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04693455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04693455.